Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase II

Model scores of the 29,894 trials active now.

Model score 20% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 8% of the time (53 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-09-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: ventricularcellsor equalheartphase ii
  Phrases that lowered it: indexinvestigateclinicaldrugpain
• Accepts healthy volunteers: No (raises risk) · Who can join
• Minimum age: 31 (lowers risk) · Who can join
• Trials the sponsor started in the prior 2 years: 157 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 8.2% (lowers risk) · Drug's FDA history
• Sponsor's past termination rate: 6.9% (lowers risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Phase: 3 (lowers risk) · Design
• Drug's FAERS reports marked serious: 70.8% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Design: parallel (raises risk) · Design
• Blinding: single (lowers risk) · Design
• Sponsor type: government (raises risk) · Sponsor's track record
• Sponsor's past trials: 173 (lowers risk) · Sponsor's track record
• Drug's FAERS reports before start: 135452 (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 25154 (raises risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design
• Primary purpose: prevention (lowers risk) · Design
• Keywords listed: 6 (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase I NCT01004406 · started 2011 · scored riskier than 83% of active trials completed
• Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI) NCT01442038 · started 2011 · scored riskier than 85% of active trials completed
• The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL) NCT01500434 · started 2009 · scored riskier than 83% of active trials completed
• The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions NCT00823212 · started 2009 · scored riskier than 82% of active trials completed
• Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting NCT02617290 · started 2017 · scored riskier than 57% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.